Term and Expiration. This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall expire upon the expiration of the last-to-expire Royalty Term for the Licensed Products in the Territory and in any event no later than the 10th anniversary of the expiration of the last Valid Claim of an [[AstraZeneca:Organization]] Patent hereunder (such period, the “Term”). On a country-by-country basis, upon the expiration of a Royalty Term in a country, the license grants to Licensee under Section 2.1 (Grants to Licensee) will become fully paid-up, perpetual, and irrevocable for such country.

Term and Expiration. This Agreement shall be binding on the Parties as of the Effective Date. Thereafter, unless terminated earlier pursuant to Section 9.2 below, this Agreement shall extend for one (1) year which may expire on a country by country basis upon the earliest to occur of either # the expiration of the Kinex Patent Rights or # invalidation of the Kinex Patent Rights (the “Agreement Term”) unless either Party gives written notice of its intention not to extend the Agreement Term: # at least ninety (90) days prior to the expiration date of the Kinex Patent Rights; or # as soon as practically possible in the case of an invalidation claim; and # thereafter, at least ninety (90) days prior to the then current annual expiration date of the Agreement.

Term and Expiration. This Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to [Section 8.2] below, this Agreement shall continue in effect until the expiration of the payment obligations of Dynavax pursuant to Article 4. Subject to [Section 8.28.2(b)], upon expiration of this Agreement, Dynavax’s license pursuant to Section 2.1 shall become fully paid-up, perpetual licenses.

Term and Expiration. The Agreement will be effective as of the Effective Date stated on the Program Enrollment and shall remain in effect until the earlier of when it naturally expires if the

Term and Expiration. The term during which an Option is exercisable shall be that period determined by the Administrator as set forth in the applicable Option Agreement, provided that no Option may be exercisable later than 10 years after the Date of Grant.

Term and Expiration. This Agreement will be effective as of the Effective Date and, unless terminated earlier by mutual written agreement of the Parties or pursuant to Sections 10.02 or 10.03, will continue in effect on a Product-by-Product basis until the expiration of Licensee’s obligations to pay Royalties under ARTICLE V (the “Term”). Upon expiration of the Royalty Term with respect to a given Product, and provided that Licensee has paid all Royalties due hereunder with respect to such Product, Licensee’s license pursuant to Section 2.01 with respect to the Development, Manufacture, and Commercialization of such Product will become a fully paid-up, non-exclusive, irrevocable, perpetual license.

Term and Expiration. This Agreement shall be effective as of the Effective Date and shall continue in effect until expiration upon the expiration of all Royalty Terms, or until earlier termination of the Agreement pursuant to [Section 10.2] (the “Term”). Upon expiration (but not earlier termination) of this Agreement, VFMCRP shall have a fully paid-up, royalty-free, perpetual and non-exclusive license (with the right to assign to Affiliates and Sublicensees), to manufacture, import, market, promote, use, develop and sell the Licensed Product in the Licensed Territory. Following such expiration (but not earlier termination) of this Agreement and for a period of ​ thereafter, Cara agrees not to commercialize (whether directly or indirectly) the Licensed Product in countries in the Licensed Territory in which VFMCRP has launched commercial sales of the Licensed Product during the term of the Agreement

Term and Expiration. Subject to ARTICLE 2, this Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall continue in force and effect on a country-by-country basis until # in the case of the [[Address A:Address]], the later of # the one hundred twentieth (120th) day following the completion of any Calendar Quarter in which # neither Party nor any of its Affiliates or its or their sublicensees has conducted any Exploitation of a Licensed Compound or Licensed Product in the Licensed Field in the [[Address A:Address]], # neither Party nor any of its Affiliates or its or their sublicensees incurred any Reimbursable Development Expenses or Allowable US Expenses in connection with the Development, Commercialization or Exploitation of Licensed Compounds or Licensed Products in the Licensed Field in the [[Address A:Address]] and # there is no Development Plan or Commercialization Plan in effect, provided that clauses (A) and (C) both remain true on such one hundred twentieth (120th) day, and # the date on which there is no Royalty-Bearing Patent with respect to any Licensed Product in the [[Address A:Address]]; and # in the case of any country in the Royalty Territory, the date the Royalty Term for a Licensed Product for use in the Licensed Field has expired in such country (the “Term”).

Term and Expiration. The term of this Agreement (the “Term”) shall commence on the Effective Date and, unless terminated earlier pursuant to this Section 8, shall expire on a Product-by-Product and country-by-country basis upon the expiration of the Royalty Term with respect to such Product, after which the licenses granted by SIRION to Bluebird in Section 2.1 with respect to such Product in such country shall become fully paid-up, royalty-free, perpetual and irrevocable.

Term and Expiration. This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall continue in force and effect until the date of expiration of the last Royalty Term for the last Licensed Product (such period, the “Term”). Following the expiration (but not earlier termination) of the Royalty Term for any Licensed Product in any country, all rights and licenses hereunder (including the grants in Section 2.1) with respect to such Licensed Product in such country shall become perpetual, irrevocable, exclusive, fully paid-up, and royalty-free, and Licensee’s development and commercialization obligations to [[AstraZeneca:Organization]] under this Agreement shall cease with respect to such Licensed Product in such country. For clarity, upon the expiration of the Term of this Agreement in its entirety, Licensee shall have a perpetual, irrevocable, fully paid-up, royalty-free right and license under the [[AstraZeneca:Organization]] Patents and [[AstraZeneca:Organization]] Know-How to subsequently Exploit in the Field any and all Licensed Products throughout the Territory, and shall have no further obligations to [[AstraZeneca:Organization]] with respect to any Licensed Products, [[AstraZeneca:Organization]] Patents, or [[AstraZeneca:Organization]] Know-How, except as set forth in Section 9.6.